Equity · Healthcare
KURA
NASDAQKura Oncology (KURA)
The line runs 12.87 USD on 24 August through 11 USD on 23 September, on a scale from 10 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.0B USD
- Revenue, year to Dec 2025
- 67.5M USD
- EPS, diluted, year to Dec 2025
- −3.18 USD
- 52-week range
- 7.39 USD – 13.59 USD
- Avg volume
- 132.1K
as of Sep 23, 2026
Have Kura Oncology (KURA) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Kura Oncology insiders reported 18 open-market sales and 3 purchases (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 19 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Nov 2026 | Powl Brian T.Chief Commercial Officer | Sell | 448 | 3K USD |
| 17 Nov 2026 | FORD KATHLEENChief Operating Officer | Sell | 3,668 | 27K USD |
| 17 Nov 2026 | Powl Brian T.Chief Commercial Officer | Sell | 15,254 | 114K USD |
| 17 Nov 2026 | Leoni MollieChief Medical Officer | Sell | 22,241 | 166K USD |
| 16 Nov 2026 | WILSON TROY EDWARDPresident and CEO | Buy | 101,119 | 750K USD |
| 16 Nov 2026 | Bair Teresa BrophyChief Legal Officer | Sell | 8,601 | 64K USD |
| 16 Nov 2026 | DOYLE THOMAS JAMESSVP, Finance & Accounting | Sell | 4,697 | 35K USD |
| 16 Nov 2026 | FORD KATHLEENChief Operating Officer | Sell | 7,042 | 52K USD |
| 16 Nov 2026 | Powl Brian T.Chief Commercial Officer | Sell | 9,196 | 68K USD |
| 16 Nov 2026 | Leoni MollieChief Medical Officer | Sell | 19,009 | 141K USD |
| 13 Nov 2026 | WILSON TROY EDWARDPresident and CEO | Buy | 98,881 | 754K USD |
| 29 Sep 2026 | FORD KATHLEENChief Operating Officer | Sell | 3,668 | 39K USD |
| Bought | 3 open-market purchases | 300,000 | $2.74M | |
| Sold | 18 open-market sales | 208,205 | $1.93M |
Showing the 12 most recent of 21 open-market trades in this window. The figures above count all of them.
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Sep 2026 | Burrows FrancisChief Scientific Officer | Option exercise | 30,000 | 185K USD |
Which funds hold Kura Oncology (KURA)?
8 of the 45 institutional funds we track reported a Kura Oncology position for the quarter ended 30 Sep 2026 — a combined 92.9M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 3,688,892 | 39.5M USD | +18.0% |
| Renaissance Technologies | Held (±25%) | 2,005,265 | 21.5M USD | +20.5% |
| Two Sigma Investments | Added | 864,401 | 9.3M USD | +415.8% |
| Citadel Advisors | Added | 680,119 | 7.3M USD | +107.3% |
| Fisher Asset Management | Held (±25%) | 565,300 | 6.1M USD | −9.7% |
| Man Group | Held (±25%) | 467,074 | 5.0M USD | +7.9% |
| Millennium Management | Trimmed | 358,402 | 3.8M USD | −49.6% |
| Tudor Investment Corp | Held (±25%) | 42,940 | 460K USD | −1.3% |
Have members of Congress traded Kura Oncology (KURA)?
The most recent congressional trade disclosed in Kura Oncology is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
What has been filed or recorded for Kura Oncology (KURA)?
The filings we hold for Kura Oncology, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 27 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 28,637 shares | 275K USD notional · 0.031% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 429 shares | 5K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.78 USD | Revenue $23M |
| 30 Sep 2026 | Financials | Total assets | 566.5M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 18.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.77 USD | Revenue $21M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.83 USD | Revenue $18M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.18 USD | Revenue $67M |
| 31 Dec 2025 | Financials | Revenue | 67.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −278.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.18 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.85 USD | Revenue $21M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.75 USD | Revenue $15M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.66 USD | Revenue $14M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.02 USD | Revenue $54M |
What do people ask about Kura Oncology (KURA)?
What did Kura Oncology shares close at?11.00
Kura Oncology closed at 11.00 USD on 23 Sep 2026, down 6.22% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Kura Oncology’s market cap?1.0B
Kura Oncology is worth 1.0B USD by market value as of 23 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Kura Oncology’s revenue?67.5M
Kura Oncology reported revenue of 67.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Kura Oncology insiders bought or sold shares recently?18 sales
In the 90 days to 22 Nov 2026, Kura Oncology insiders reported 18 open-market sales and 3 purchases (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Kura Oncology?8 of 45
8 of the 45 funds we track reported a Kura Oncology position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Two Sigma Investments. See Funds
Have members of Congress traded Kura Oncology?1 trade
Yes. 1 trade in Kura Oncology appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Kura Oncology last report earnings?−0.78
Kura Oncology last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.78 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words